TY - JOUR AU - Elphee, E. E. PY - 2008 DA - 2008// TI - Caring for patients with chronic lymphocytic leukaemia JO - Clinical Journal of Oncology Nursing VL - 12 UR - https://doi.org/10.1188/08.CJON.417-423 DO - 10.1188/08.CJON.417-423 ID - Elphee2008 ER - TY - JOUR AU - Hayat, M. J. AU - Howlader, N. AU - Reichman, M. E. AU - Edwards, B. K. PY - 2007 DA - 2007// TI - Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program JO - Oncologist VL - 12 UR - https://doi.org/10.1634/theoncologist.12-1-20 DO - 10.1634/theoncologist.12-1-20 ID - Hayat2007 ER - TY - JOUR AU - Shanafelt, T. D. AU - Bowen, D. AU - Venkat, C. AU - Slager, S. L. AU - Zent, C. S. AU - Kay, N. E. AU - Reinalda, M. AU - Sloan, J. A. AU - Call, T. G. PY - 2007 DA - 2007// TI - Quality of life in chronic lymphocytic leukaemia: An international survey of 1482 patients JO - British Journal of Haematology VL - 139 UR - https://doi.org/10.1111/j.1365-2141.2007.06791.x DO - 10.1111/j.1365-2141.2007.06791.x ID - Shanafelt2007 ER - TY - BOOK PY - 2008 DA - 2008// TI - Guide to the Methods of Technology Appraisal PB - NICE CY - London ID - ref4 ER - TY - STD TI - Scottish Medicines Consortium Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF) (Revised June 2007). accessed 11/20/09 [http://www.scottishmedicines.org.uk/smc/22.html] UR - http://www.scottishmedicines.org.uk/smc/22.html ID - ref5 ER - TY - JOUR AU - Scott, W. G. AU - Scott, H. M. PY - 2007 DA - 2007// TI - Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia JO - Clin Drug Investig VL - 27 UR - https://doi.org/10.2165/00044011-200727110-00002 DO - 10.2165/00044011-200727110-00002 ID - Scott2007 ER - TY - JOUR AU - Reed, S. D. AU - Anstrom, K. J. AU - Li, Y. AU - Schulman, K. A. PY - 2008 DA - 2008// TI - Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia JO - Pharmacoeconomics VL - 26 UR - https://doi.org/10.2165/00019053-200826050-00007 DO - 10.2165/00019053-200826050-00007 ID - Reed2008 ER - TY - JOUR AU - Breitscheidel, L. PY - 2008 DA - 2008// TI - Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia JO - J Med Econ VL - 11 UR - https://doi.org/10.3111/13696990802354683 DO - 10.3111/13696990802354683 ID - Breitscheidel2008 ER - TY - JOUR AU - Levy, V. AU - Porcher, R. AU - Delabarre, F. AU - Leporrier, M. AU - Cazin, B. AU - Chevret, S. PY - 2001 DA - 2001// TI - Evaluating treatment strategies in chronic lymphocytic leukaemia: Use of quality-adjusted survival analysis JO - Journal of Clinical Epidemiology VL - 54 UR - https://doi.org/10.1016/S0895-4356(00)00359-0 DO - 10.1016/S0895-4356(00)00359-0 ID - Levy2001 ER - TY - JOUR AU - Stephens, J. M. AU - Gramegna, P. AU - Laskin, B. AU - Botteman, M. F. AU - Pashos, C. L. PY - 2005 DA - 2005// TI - Chronic lymphocytic leukaemia: Economic burden and quality of life: Literature review JO - American Journal of Therapeutics VL - 12 UR - https://doi.org/10.1097/01.mjt.0000104489.93653.0f DO - 10.1097/01.mjt.0000104489.93653.0f ID - Stephens2005 ER - TY - JOUR AU - Hyde, B. AU - Wake, B. AU - Bryan, S. AU - Barton, P. AU - Fry-Smith, A. AU - Davenport, C. AU - Song, F. PY - 2002 DA - 2002// TI - Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment JO - Health Technology Assessment VL - 6 UR - https://doi.org/10.3310/hta6020 DO - 10.3310/hta6020 ID - Hyde2002 ER - TY - CHAP PY - 2001 DA - 2001// BT - Cost-effectiveness ID - ref12 ER - TY - JOUR AU - Berterö, C. AU - Eriksson, B. E. AU - Ek, A. C. PY - 1997 DA - 1997// TI - A substantive theory of quality of life of adults with chronic leukaemia JO - International Journal of Nursing Studies VL - 34 UR - https://doi.org/10.1016/S0020-7489(96)00025-9 DO - 10.1016/S0020-7489(96)00025-9 ID - Berterö1997 ER - TY - JOUR AU - Pickard, A. S. AU - Wilke, C. T. AU - Lin, H. W. AU - Lloyd, A. PY - 2007 DA - 2007// TI - Health utilities using the EQ-5D in studies of cancer JO - Pharmacoeconomics VL - 25 UR - https://doi.org/10.2165/00019053-200725050-00002 DO - 10.2165/00019053-200725050-00002 ID - Pickard2007 ER - TY - JOUR AU - Torrance, G. W. PY - 1986 DA - 1986// TI - Measurement of health state utilities for economic appraisal JO - Journal Health Economics VL - 5 UR - https://doi.org/10.1016/0167-6296(86)90020-2 DO - 10.1016/0167-6296(86)90020-2 ID - Torrance1986 ER - TY - JOUR AU - Redaelli, A. AU - Stephens, J. M. AU - Laskin, B. L. AU - Pashos, C. L. AU - Botteman, M. F. PY - 2003 DA - 2003// TI - The burden and outcomes associated with four leukaemias: AML, ALL, CLL and CML JO - Expert Review of Anticancer Therapy VL - 3 UR - https://doi.org/10.1586/14737140.3.3.311 DO - 10.1586/14737140.3.3.311 ID - Redaelli2003 ER - TY - JOUR AU - Kermani, I. A. AU - Dehdilani, M. AU - Dolatkhah, R. PY - 2007 DA - 2007// TI - Chronic lymphocytic leukaemia in the recent 10 years and treatment effects of Fludarabin JO - Asian Pacific Journal of Cancer Prevention VL - 8 ID - Kermani2007 ER - TY - JOUR AU - Holzner, B. AU - Kemmler, G. AU - Kopp, M. AU - Nguyen-Van-Tam, D. AU - Sperner-Unterweger, B. AU - Greil, R. PY - 2004 DA - 2004// TI - Quality of life of patients with chronic lymphocytic leukaemia: Results of a longitudinal investigation over 1 yr JO - European Journal of Haematology VL - 72 UR - https://doi.org/10.1111/j.1600-0609.2004.00233.x DO - 10.1111/j.1600-0609.2004.00233.x ID - Holzner2004 ER - TY - JOUR AU - Else, M. AU - Smith, A. G. AU - Cocks, K. PY - 2008 DA - 2008// TI - Patients' experience of chronic lymphocytic leukaemia: Baseline health-related quality of life results from the LRF CLL4 trial JO - British Journal of Haematology VL - 143 UR - https://doi.org/10.1111/j.1365-2141.2008.07407.x DO - 10.1111/j.1365-2141.2008.07407.x ID - Else2008 ER - TY - JOUR AU - Cheson, B. D. AU - Bennett, J. M. AU - Grever, M. AU - Kay, N. AU - Keating, M. J. AU - O'Brien, S. AU - Rai, R. K. PY - 1996 DA - 1996// TI - National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukaemia: Revised guidelines for diagnosis and treatment JO - Blood VL - 87 ID - Cheson1996 ER - TY - CHAP PY - 2006 DA - 2006// BT - Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS ID - ref21 ER - TY - STD TI - Office of National Statistics Online 2009: Population Estimates for UK, England and Wales, Scotland and Northern Ireland.[http://www.statistics.gov.uk/statbase/Product.asp?vlnk=15106] UR - http://www.statistics.gov.uk/statbase/Product.asp?vlnk=15106 ID - ref22 ER - TY - JOUR AU - Uyl-De Groot, C. A. AU - Löwenberg, B. AU - Vellenga, E. AU - Suciu, S. AU - Willemze, R. AU - Rutten, F. F. H. PY - 1998 DA - 1998// TI - Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia JO - Br J Haematology VL - 100 UR - https://doi.org/10.1046/j.1365-2141.1998.00635.x DO - 10.1046/j.1365-2141.1998.00635.x ID - Uyl-De Groot1998 ER - TY - JOUR AU - Lloyd, A. AU - Nafees, B. AU - Narewska, J. AU - Dewilde, S. AU - Watkins, J. PY - 2006 DA - 2006// TI - Health state utilities for metastatic breast cancer JO - Br J Cancer VL - 95 UR - https://doi.org/10.1038/sj.bjc.6603326 DO - 10.1038/sj.bjc.6603326 ID - Lloyd2006 ER - TY - JOUR AU - Beusterien, K. M. AU - Szabo, S. M. AU - Kotapati, S. AU - Mukherjee, J. AU - Hoos, A. AU - Hersey, P. AU - Middleton, M. R. AU - Levy, A. R. PY - 2009 DA - 2009// TI - Societal preference values for advanced melanoma health states in the United Kingdom and Australia JO - Br J Cancer VL - 101 UR - https://doi.org/10.1038/sj.bjc.6605187 DO - 10.1038/sj.bjc.6605187 ID - Beusterien2009 ER - TY - JOUR AU - Szabo, S. M. AU - Levy, A. R. AU - Davis, C. AU - Holyoake, T. L. AU - Cortes, J. PY - 2009 DA - 2009// TI - A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukaemia JO - Value Health VL - 13 UR - https://doi.org/10.1111/j.1524-4733.2009.00573.x DO - 10.1111/j.1524-4733.2009.00573.x ID - Szabo2009 ER - TY - CHAP AU - Bennett, K. AU - Torrance, G. ED - Spilker, B. PY - 1996 DA - 1996// TI - Measuring health state preferences and utilities: Rating scale, time trade-off and standard gamble techniques BT - Quality of Life and Pharmacoeconomics in Clinical Trials PB - Lippincott-Raven CY - Philadelphia ID - Bennett1996 ER - TY - JOUR AU - Dolan, P. PY - 1997 DA - 1997// TI - Modeling valuations for EuroQol health states JO - Medical Care VL - 35 UR - https://doi.org/10.1097/00005650-199711000-00002 DO - 10.1097/00005650-199711000-00002 ID - Dolan1997 ER - TY - JOUR AU - Sullivan, P. W. AU - Lawrence, W. F. AU - Ghushchyan, V. PY - 2005 DA - 2005// TI - A national catalog of preference-based scores for chronic conditions in the United States JO - Medical Care VL - 43 UR - https://doi.org/10.1097/01.mlr.0000172050.67085.4f DO - 10.1097/01.mlr.0000172050.67085.4f ID - Sullivan2005 ER - TY - JOUR AU - Tsuchiya, A. AU - Ikeda, S. AU - Ikegami, N. AU - Nishimura, S. AU - Sakai, I. AU - Fukuda, T. AU - Hamashima, C. AU - Hisashige, A. AU - Tamura, M. PY - 2002 DA - 2002// TI - Estimating an EQ-5D population value set: The case of Japan JO - Health Economics VL - 11 UR - https://doi.org/10.1002/hec.673 DO - 10.1002/hec.673 ID - Tsuchiya2002 ER - TY - JOUR AU - Levy, A. R. AU - Krowdley, K. AU - Iloeje, U. H. AU - Tafesse, E. AU - Mukherjee, J. AU - Gish, R. AU - Bzowej, N. AU - Briggs, A. H. PY - 2008 DA - 2008// TI - The impact of chronic hepatitis B disease progression on quality of life: A multinational study of health state preferences from infected and uninfected persons JO - Value in Health VL - 11 UR - https://doi.org/10.1111/j.1524-4733.2007.00297.x DO - 10.1111/j.1524-4733.2007.00297.x ID - Levy2008 ER - TY - JOUR AU - Dale, W. AU - Basu, A. AU - Elstein, A. AU - Meltzer, D. PY - 2008 DA - 2008// TI - Predicting Utility Ratings for Joint Health States from Single Health States in Prostate Cancer: Empirical Testing of 3 Alternative Theories JO - Med Dec Making VL - 28 UR - https://doi.org/10.1177/0272989X07309639 DO - 10.1177/0272989X07309639 ID - Dale2008 ER - TY - JOUR AU - Fu, A. X. AU - Kattan, M. W. PY - 2008 DA - 2008// TI - Utilities should not be multiplied: evidence from the preference-based scores in the United States JO - Med Care VL - 46 UR - https://doi.org/10.1097/MLR.0b013e3181791a9c DO - 10.1097/MLR.0b013e3181791a9c ID - Fu2008 ER - TY - JOUR AU - Rabin, R. AU - de Charro, F. PY - 2001 DA - 2001// TI - EQ-5D: a measure of health status from the EuroQol Group JO - Annals of Medicine VL - 33 UR - https://doi.org/10.3109/07853890109002087 DO - 10.3109/07853890109002087 ID - Rabin2001 ER - TY - JOUR AU - Kilbridge, K. L. AU - Cole, B. F. AU - Kirkwood, J. M. AU - Haluska, F. G. AU - Atkins, M. A. AU - Ruckdeschel, J. C. AU - Sock, D. E. AU - Nease, R. F. AU - Weeks, J. C. PY - 2002 DA - 2002// TI - Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.20.5.1311 DO - 10.1200/JCO.20.5.1311 ID - Kilbridge2002 ER - TY - JOUR AU - Crott, R. PY - 2004 DA - 2004// TI - Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review JO - Pharmacoeconomics VL - 22 UR - https://doi.org/10.2165/00019053-200422090-00002 DO - 10.2165/00019053-200422090-00002 ID - Crott2004 ER - TY - JOUR AU - Dixon, S. AU - Walters, S. J. AU - Turner, L. AU - Hancock, B. W. PY - 2006 DA - 2006// TI - Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial JO - Br J Cancer VL - 94 UR - https://doi.org/10.1038/sj.bjc.6602973 DO - 10.1038/sj.bjc.6602973 ID - Dixon2006 ER -